Quotient logo

QTNT - Quotient Share Price

$7.77 -0.1  -1.0%

Last Trade - 8:55pm

Sector
Healthcare
Size
Mid Cap
Market Cap £505.3m
Enterprise Value £548.8m
Revenue £26.1m
Position in Universe 2680th / 6347
Bullish
Bearish
Unlock QTNT Revenue
Momentum
Relative Strength (%)
1m +23.6%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -30.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
18.4 18.5 22.2 24.7 29.1 32.7 36.0 68.1 +12.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 March 2020, Quotient Ltd revenues increased 12% to $32.7M. Net loss decreased 2% to $102.8M. Revenues reflect United States segment increase of 21% to $17.8M, France segment increase of 9% to $7.1M. Lower net loss reflects Other, Net increase from $6.4M (expense) to $2.4M (income), Compensation expense in respect of share decrease of 10% to $4.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

QTNT Revenue Unlock QTNT Revenue

Net Income

QTNT Net Income Unlock QTNT Revenue

Normalised EPS

QTNT Normalised EPS Unlock QTNT Revenue

PE Ratio Range

QTNT PE Ratio Range Unlock QTNT Revenue

Dividend Yield Range

QTNT Dividend Yield Range Unlock QTNT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
QTNT EPS Forecasts Unlock QTNT Revenue
Profile Summary

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Directors
Last Annual March 31st, 2020
Last Interim March 31st, 2020
Incorporated January 18, 2012
Public Since April 16, 2014
No. of Shareholders: 21
No. of Employees: 418
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 80,398,326
Free Float (0.0%)
Eligible for
ISAs
SIPPs
QTNT Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for QTNT
Upcoming Events for QTNT
Frequently Asked Questions for Quotient
What is the Quotient share price?

As of 8:55pm, shares in Quotient are trading at $7.77, giving the company a market capitalisation of £505.3m. This share price information is delayed by 15 minutes.

How has the Quotient share price performed this year?

Shares in Quotient are currently trading at $7.77 and the price has moved by -16.22% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Quotient price has moved by -20.35% over the past year.

What are the analyst and broker recommendations for Quotient?

Of the analysts with advisory recommendations for Quotient, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Quotient is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Quotient next release its financial results?

Quotient is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Quotient dividend yield?

Quotient does not currently pay a dividend.

Does Quotient pay a dividend?

Quotient does not currently pay a dividend.

When does Quotient next pay dividends?

Quotient does not currently pay a dividend.

How do I buy Quotient shares?

To buy shares in Quotient you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Quotient?

Shares in Quotient are currently trading at $7.77, giving the company a market capitalisation of £505.3m.

Where are Quotient shares listed? Where are Quotient shares listed?

Here are the trading details for Quotient:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: QTNT
What kind of share is Quotient?

Based on an overall assessment of its quality, value and momentum, Quotient is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Quotient share price forecast 2020?

Shares in Quotient are currently priced at $7.77. At that level they are trading at 71.97% discount to the analyst consensus target price of 0.00.

Analysts covering Quotient currently have a consensus Earnings Per Share (EPS) forecast of -1.34 for the next financial year.

How can I tell whether the Quotient share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quotient. Over the past six months, the relative strength of its shares against the market has been -8.95%. At the current price of $7.77, shares in Quotient are trading at 6.18% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Quotient PE Ratio?

We were not able to find PE ratio data for Quotient.

Who are the key directors of Quotient?

Quotient's management team is headed by:

Jeremy Stackawitz - CPR
Edward Farrell - CPR
Thomas Bologna - IND
Frederick Hallsworth - IND
Brian McDonough - IND
Zubeen Shroff - IND
Sarah O'Connor - IND
Heino.N.F.M von Prondzynski - CHM
Franz Walt - CEO
Ernest Larnach - EVF
Peter Buhler - CFO
Who are the major shareholders of Quotient?

Here are the top five shareholders of Quotient based on the size of their shareholding:

Perceptive Advisors LLC Private Equity
Percentage owned: 16.53% (13.3m shares)
Polar Capital LLP Investment Advisor/Hedge Fund
Percentage owned: 9.47% (7.61m shares)
Galen Partners Private Equity
Percentage owned: 9.12% (7.33m shares)
Polar Capital Funds Plc - Healthcare Opportunities Fund Mutual Fund
Percentage owned: 6.77% (5.45m shares)
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund
Percentage owned: 5.23% (4.20m shares)
Similar to QTNT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.